Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Sellas Life Sciences Group I (SLS)

161 + Investors. Track Smart Money conviction in SLS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +46
Streak
5Q ▲
Buyers last Q
73%

Smart Money Signals — SLS

Based on 161 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 5 quarters in a row

last 6Q
For 5 consecutive quarters, more hedge funds added SLS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
161 hedge funds hold SLS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +266% more funds vs a year ago

fund count last 6Q
+117 new funds entered over the past year (+266% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 73% buying

117 buying43 selling
Last quarter: 117 funds were net buyers (62 opened a brand new position + 55 added to an existing one). Only 43 were sellers (27 trimmed + 16 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+29 vs last Q)

new funds entering per quarter
Funds opening a new SLS position: 40 → 21 → 33 → 62. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 57% entered in last year

■ 16% conviction (2yr+) ■ 27% medium ■ 57% new
Only 26 funds (16%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +63% but shares only +47% — price-driven

Value
+62%
Shares
+46%
Last quarter: the total dollar value of institutional holdings rose +63%, but actual share count only changed +47%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

17 → 40 → 21 → 33 → 62 new funds/Q
New funds entering each quarter: 40 → 21 → 33 → 62. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🌱

Early stage — 69% of holders entered in last year

■ 27% veterans ■ 4% 1-2yr ■ 69% new
Of 172 current holders: 119 (69%) entered in the past year, only 46 (27%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
🏆

Elite ownership — 54% AUM from top-100 funds

54% from top-100 AUM funds
35 of 161 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in SLS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
6.3
out of 10
Moderate Exit Risk
Exit risk score 6.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — SLS

In 2026 Q1, 117 hedge funds were net buyers of SLS (62 opened a new position, 55 added to an existing one), while 43 reduced or exited (27 trimmed, 16 sold completely) — a 73% buyer ratio, indicating clear institutional accumulation. This marks 5 consecutive quarters of net institutional buying — a persistent conviction signal. 54% of total institutional value in SLS is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +46 funds (more new holders than closures). Total institutional holders: 161.

Hedge Fund Ownership: SLS

How many hedge funds hold SLS — quarterly history vs. share price
Quarterly hedge fund ownership of SLS vs. share price

Market Analysis: SLS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: SLS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Sellas Life Sciences Group I (SLS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much SLS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
SLS
+83.5%
XLV
+2.8%

SLS outperformed XLV by +80.7% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
SLS
+9.6%
XLV
+3.9%

Since the filing became public, SLS outperformed XLV by +5.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

15 top-rated funds 0 high-conviction
Consensus
5.2
/ 10
breadth
×
Elite
0.5
/ 10
conviction
Hedge Fund Positioning: SLS
161 + Investors

Track Smart Money conviction in SLS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 161 115 40.0%
13F Shares 70M 47M 46.69%
Total Value $291M $179M 62.74%
New Positions 62 33 +29
Increased Positions 54 52 +2
Closed Positions 16 10 +6
Reduced Positions 23 16 +7
Total Calls 10 10 -
Total Puts 6 7 -14.29%
PUT/CALL Ratio 0.6 0.7 Bullish

Statistics: SLS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

161 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in SLS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 SLS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Vision Financial Markets LLC 1.26% 304,400 $1.3M
2 Dagco, INC. 0.94% 1,028,780 $4.4M
3 Fulcrum Wealth Advisors, LLC 0.38% 109,251 $462K
4 Diadema Partners LP 0.22% 300,000 $1.3M
5 Everhart Financial Group, Inc. 0.13% 364,397 $1.5M
6 Scientech Research LLC 0.12% 34,096 $144K
7 Instrumental Wealth, LLC 0.12% 44,914 $190K
8 Visionary Horizons, LLC 0.08% 36,000 $152K
9 Grange Capital, LLC 0.07% 17,651 $75K
10 Oxford Asset Management LLP 0.06% 35,501 $150K
11 EntryPoint Capital, LLC 0.06% 48,224 $204K
12 Financial Designs Corp 0.05% 23,327 $99K
13 Fulcrum Wealth Advisors, LLC 0.05% 15,500 $66K
14 Genesee Capital Advisors, LLC 0.05% 30,000 $127K
15 Millington Financial Advisors, LLC 0.05% 25,000 $122K
16 NORTHSTAR ASSET MANAGEMENT Co 0.05% 50,000 $212K
17 Caitong International Asset Management Co., Ltd 0.05% 60,712 $257K
18 ELCO Management Co., LLC 0.03% 14,609 $62K
19 Tema Etfs LLC 0.03% 90,007 $381K
20 Scissortail Wealth Management, LLC 0.02% 27,322 $116K
21 Accurate Wealth Management, LLC 0.02% 32,611 $159K
22 Profund Advisors LLC 0.02% 111,794 $473K
23 SJS Investment Consulting Inc. 0.01% 25,000 $106K
24 Ewa, LLC 0.01% 12,796 $54K
25 Private Wealth Management Group, LLC 0.01% 10,000 $42K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Sellas Life Sciences Group I (SLS)

What does the Smart Money Trend signal show for SLS?

Buying streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds added SLS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for SLS?

More buyers than sellers — 73% buying: Last quarter: 117 funds were net buyers (62 opened a brand new position + 55 added to an existing one). Only 43 were sellers (27 trimmed + 16 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for SLS holders?

Elite ownership — 54% AUM from top-100 funds: 35 of 161 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in SLS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held SLS?

Mostly new holders — 57% entered in last year: Only 26 funds (16%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Sellas Life Sciences Group I (SLS) following the 2026 Q1 hedge fund 13F filings?

As of today, SLS has moved +9.6% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +5.7%. Since the quarter end (March 31, 2026), SLS has gained +83.5% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →